共查询到20条相似文献,搜索用时 15 毫秒
1.
Min Kim Seul Young Kim Woo Sun Rou Se Woong Hwang Byung Seok Lee 《Clinical and molecular hepatology》2015,21(4):352-357
Background/Aims
Despite sexual function making an important contribution to the quality of life, data on erectile function are relatively scant in patients with chronic liver disease. We evaluated the prevalence of and risk factors for erectile dysfunction (ED) in patients with liver disease related to hepatitis B, especially among those with chronic hepatitis B (CHB) or early-stage cirrhosis.Methods
In total, 69 patients (35 with CHB and 34 with hepatitis-B-related liver cirrhosis [HBV-LC]) aged 40-59 years were analyzed. Child-Pugh classes of A and B were present in 30 (88.2%) and 4 (11.8%) of the patients with HBV-LC, respectively. The erectile function of the patients was evaluated using the Korean version of IIEF-5.Results
The prevalence of any ED was 24.6% for all patients, and 8.6% and 41.2% for those with CHB and HBV-LC, respectively (P=0.002). While there was only one (2.9%) CHB patient for each stage of ED, mild, moderate, and severe ED stages were seen in three (8.8%), one (2.9%), and ten (29.4%) of the HBV-LC patients, respectively. Multiple regression analysis identified the type of liver disease (P=0.010), hypertension (P=0.022), score on the Beck Depression Inventory (P =0.044), and the serum albumin level (P=0.014) as significant independent factors for the presence of ED.Conclusions
The prevalence of ED was significantly higher in patients with early-stage HBV-LC than in those with CHB. Therefore, screening male patients with early viral cirrhosis for ED and providing appropriate support are needed, especially when the cirrhosis is accompanied by hypertension, depression, or a depressed level of serum albumin. 相似文献2.
In Ku Yo Oh Sang Kwon Jin Woong Park Jong Joon Lee Jung Hyun Lee In Sik Won Sun Young Na Pil Kyu Jang Pyung Hwa Park Duck Joo Choi Yun Soo Kim Ju Hyun Kim 《Clinical and molecular hepatology》2015,21(1):32-40
Background/Aims
Liver stiffness (LS) as assessed by transient elastography (TE) can change longitudinally in patients with chronic hepatitis B (CHB). The aim of this study was to identify the factors that improve LS.Methods
Between April 2007 and December 2012, 151 patients with CHB who underwent two TE procedures with an interval of about 2 years were enrolled. Ninety-six of the 151 patients were treated with nucleos(t)ide analogues [the antiviral therapy (+) group], while the remaining 55 patients were not [the antiviral therapy (-) group]. The two groups of patients were stratified according to whether they exhibited an improvement or a deterioration in LS during the study period (defined as an LS change of ≤0 or >0 kPa, respectively, over a 1-year period), and their data were compared.Results
No differences were observed between the antiviral therapy (+) and (-) groups with respect to either their clinical characteristics or their initial LS. The observed LS improvement was significantly greater in the antiviral therapy (+) group than in the antiviral therapy (-) group (-3.0 vs. 0.98 kPa, P=0.011). In the antiviral therapy (+) group, the initial LS was higher in the LS improvement group (n=63) than in the LS deterioration group (n=33; 7.9 vs. 4.8 kPa, P<0.001). However, there were no differences in any other clinical characteristic. In the antiviral therapy (-) group, the initial LS was also higher in the LS improvement group (n=29) than in the LS deterioration group (n=26; 8.3 vs. 6.5 kPa, P=0.021), with no differences in any other clinical characteristic.Conclusions
A higher initial LS was the only factor associated with LS improvement in patients with CHB in this study. 相似文献3.
Gupta E Kumar A Choudhary A Kumar M Sarin SK 《Indian journal of medical microbiology》2012,30(2):150-154
Purpose: The hallmark of chronic hepatitis B (CHB) infection is the presence of hepatitis B surface antigen (HBsAg) positivity for at least 6 months. Recently, serum levels of HBsAg have been compared with serum HBV DNA as a surrogate marker to monitor CHB patients. However, data correlating these two markers are scarce. Hence, the present study was done to correlate HBV DNA with HBsAg in CHB patients. Materials and Methods: Consecutive patients of CHB were included. HBV DNA was measured by real-time polymerase chain reaction (PCR). Serum HBsAg was measured by Architect HBsAg. Results: Of the 198 patients enrolled, 166 fulfilled the inclusion criteria (mean age 43 ± 14 years, 87% males) and the median HBV DNA was 1.7 × 103 (range 6.0–1.1 × 108) IU/ml. Median HBsAg was 8.7 × 103 (range 5.0–3.2 × 105) IU/ml. Overall correlation between HBV DNA and HBsAg was weak but significant (Spearman ρ = 0.443, P < 0.01). Correlation in HBe antigen-positive group was better (ρ = 0.402, P < 0.01) in comparison to HBe antigen-negative group (ρ = 0.193 P = 0.05). Good correlation existed in treatment-naïve group (ρ = 0.538, P < 0.01). Correlation was regardless of normal or raised alanine transaminase (ALT). Eighty (48%) patients had high HBV DNA (≥2000 IU/ml). Correlation in high DNA group was significant (P < 0.01). The best cut-off of HBsAg for diagnosing high DNA is 3.36 ×103 IU/ml. Conclusions: Serum HBsAg correlates with HBV DNA in CHB patients, especially in high serum HBV DNA, HBe antigen-positive and treatment-naïve group. HBsAg levels can be used for predicting high serum HBV DNA levels. 相似文献
4.
5.
病毒性肝炎肝细胞凋亡及与肝纤维化的关系 总被引:5,自引:0,他引:5
目的 研究病毒性肝炎肝细胞凋亡及与肝纤维化的关系。方法 以原位末端标记及免疫组化检测40例慢性病毒性肝炎(CH)肝组织细胞调亡相关线状断裂DNA以及Fas抗原、转化生长因子β1(TGF-β1)、Ⅲ型前胶原肽(PⅢP)在肝组织中的表达;以酶联免疫吸附测定(ELISA)检测血清可溶性Fas(sFas)及TGF-β1。结果 CH肝细胞DNA损伤与肝组织Fas抗原、TGF-β1表达及血清sFas、TGF- 相似文献
6.
Yuan Liao Jiao Gong Wenying Zhou Huimin Dong Jiayin Liang Minqi Luo Bo Hu 《Journal of medical virology》2019,91(4):642-649
Chronic liver inflammation caused by chronic hepatitis B virus (CHB) infection leads to liver cirrhosis and hepatocellular carcinoma. Recently, the role of alanine aminotransferase (ALT) as a predictor of liver inflammation has been questioned. The aim of this study was to investigate the utility of noninvasive fibrosis markers including hyaluronic acid (HA), collagen type IV (CIV), N-terminal propeptide of type III procollagen (PIIINP), and laminin (LN) in identifying significant liver inflammation in patients with CHB, especially in patients with normal or near-normal ALT. A total of 242 CHB patients who underwent liver biopsy were enrolled. The serum levels of ALT, aspartate aminotransferase, HA, CIV, PIIINP, and LN were quantified and the relationship between histological staging and serum markers was systematically analyzed. Serum CIV, PIIINP, HA, and LN levels increased significantly along with the increasing severity of liver inflammation. Multivariate analysis showed that CIV and LN were independently associated with significant inflammation. CIV, PIIINP, HA, and LN levels were found to have high diagnostic values for predicting significant inflammation in patients with CHB (area under the curve, AUC = 0.807, 0.795, 0.767, and 0.703, respectively). The combined index for the identification of significant inflammation, including CIV, PIIINP, HA, and LN levels, significantly improved diagnostic performance (AUC = 0.851). Moreover, the combined index also achieved excellent diagnostic accuracy (AUC = 0.861) in patients with CHB with normal or near-normal ALT. In conclusion, the combined index may be a strong indicator for discriminating significant liver inflammation, especially in patients with CHB with normal or near-normal ALT. 相似文献
7.
目的 探讨血清和肝组织TGF-β1水平与慢性乙肝肝纤维化程度的关系,为肝纤维化诊断提供依据.方法 以肝活检病理诊断区分131例慢性HBV感染者纤维化程度(S0~S4),用ELISA法检测血清TGF-β1水平,免疫组化法检测肝组织TGF-β1表达并半定量.分析血清TGF-β1和肝组织TGF-β1表达与肝纤维化程度的关系.结果 血清和肝组织TGF-β1均与肝纤维化程度具有非常显著性正相关(r分别是0.74和0.89,P<0.01).血清TGF-β1各组间比较差异有统计学意义(P<0.01).组问分割比较,S0和S1分别与S4比较差异均有统计学意义(P<0.005);各组与S0组比较差异均有统计学意义(P<0.005);S1组和S3组之间比较有统计学意义(P<0.005).肝组织TGF-β1表达在S3和S4组之间比较差异无统计学意义(P>0.05),其余组间比较差异均有统计学意义(P<0.01).血清TGF-β1和肝组织TGF-β1表达具有非常显著性意义相关(r=0.61,P<0.01).结论 血清TGF-β1和肝组织TGF-β1水平与慢乙肝肝纤维化程度相关,血清TGF-β1有希望成为临床判断轻度或重度肝纤维化的无创伤性诊断指标. 相似文献
8.
Ioanna Aggeletopoulou Panagiota Davoulou Christos Konstantakis Konstantinos Thomopoulos Christos Triantos 《Reviews in medical virology》2017,27(6)
Hepatitis B vaccination is strongly recommended for all infants and children but also for adults who are at risk of HBV infection. Attempts to immunize patients with liver cirrhosis have been proven relatively ineffective, and several strategies have already been used to improve the immune response in this group. The primary aim of this review is to examine, discuss, and summarize the immunogenicity of hepatitis B vaccination in patients with liver cirrhosis. MEDLINE search identified 11 studies (n = 961). The dose of the vaccine and the schedule of the vaccination varied. The response rates to the HBV vaccination ranged from 16% to 87% among patients with cirrhosis regardless of the number and vaccine dose. In particular, patients who received the standard dose of vaccination achieved seroprotection rates ranged from 16% to 79% (mean response rate 38%) and those who received a double dose achieved relatively better seroprotection rates (range: 26%‐87%; mean response rate 53%). The overall mean response rate to the HBV vaccination was 47%. In conclusion, cirrhotic patients achieve lower seroprotection rates after the completion of HBV vaccination series. Several strategies have tried to improve the immunogenicity; however, there is a great need for additional studies to further explore (1) the immune response in relation to poor vaccination responsiveness confounding factors, (2) novel strategies to improve immunogenicity, and (3) the immune mechanism underlying the differences in response rates to HBV vaccination. 相似文献
9.
目的:探讨破血逐瘀经典方剂“大黄蟅虫丸”对乙型肝炎后肝纤维化的治疗作用。 方法: 将乙型慢性肝炎患者92例,随机分为两组,治疗组与对照组,治疗组使用大黄蟅虫丸,对照组使用甘利欣治疗,疗程均为6个月,分别检测两组治疗前后透明质酸(HA)、血清Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)、层粘蛋白(LN)、丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、白蛋白与球蛋白比(A/G),并进行对比观察。 结果: 经过治疗后,两组血清LN、Ⅳ型胶原、ALT、AST均显著下降(P<0.01),但治疗组LN、Ⅳ型胶原水平下降较之对照组更明显(P<0.05),而对于ALT、AST,两组治疗后无差异;另经治疗后,治疗组血清HA、PCⅢ水平下降(P<0.01),A/G水平升高(P<0.01),而对照组的血清HA、PCⅢ、A/G水平无明显变化(P>0.05)。 结论: 大黄着蟅虫丸对乙型肝炎后肝纤维化有一定的治疗作用。 相似文献
10.
Massimo Rugge Maria Guido Flavia Bortolotti Mauro Cassaro Paolo Cadrobbi Franco Noventa Giuseppe Realdi 《Virchows Archiv : an international journal of pathology》1991,419(2):93-97
Summary Forty chronic untreated paediatric carriers of hepatitis B virus (HBV) infection, with no other causes of liver disease, were biopsied on presentation, when the disease was in the active viral replication phase. After a period ranging from 1 to 13 years, all patients underwent a control biopsy. At the time of the last biopsy, 31 of the patients were anti-HBe positive, whereas 9 persisted in the active replication phase. In this latter phase, necrotic and inflammatory lesions and the presence of nuclear HBcAg were found significantly more frequently than when replication had terminated. The necrotic and inflammatory lesions detected in the first biopsy of patients who subsequently underwent antiHBe seroconversion were significantly more severe than in patients failing to reach seroconversion. All patients who maintained viral replication showed generalized nuclear reactivity for HBcAg on presentation; such reactivity was also found in 16 of 31 (52%) patients who reached anti-HBeAg seroconversion. All these cases had piecemeal necrosis (PMN) in the biopsy. PMN may therefore be considered as a positive prognostic factor in that it identifies those patients who may seroconvert with significant remission of liver disease 相似文献
11.
Ji Chen Suhui Yu Zhichao Lang Yan Jin Guangyao Zhou Qiqi Tao Xiaodong Wang Jianjian Zheng 《Journal of medical virology》2023,95(1):e28239
We aimed to develop and validate a novel combined score to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B (CHB). In this study, a total of 331 CHB patients from three cohorts who underwent liver biopsy were enrolled, and the Scheuer system was used for liver fibrosis classification. The combined score was derived by principal component analysis of key differentially expressed genes. For significant liver fibrosis (≥S2), the areas under the receiver operating characteristics curves (AUROCs) of the combined score were 0.838, 0.842, and 0.881 in the three cohorts, respectively. And for advanced liver fibrosis (≥S3), the AUROCs were 0.794, 0.801, and 0.901, respectively. Compared with the results of AUROCs for aspartate aminotransferase≥to≥platelet ratio (APRI) and fibrosis index based on four factors (FIB-4) in the validation cohorts, better clinical diagnostic value for assessing the progression of liver fibrosis was found in the combined score. Additionally, univariate ordered logistic regression analysis indicated that the combined score could serve as a more superior and stable risk factor than APRI and FIB-4 in the assessment of liver fibrosis. For CHB patients with normal alanine aminotransferase (ALT), our results further emphasized the diagnostic value of the combined score for significant fibrosis (≥S2) and advanced fibrosis (≥S3). Moreover, it was found that patients with the high combined score, who were associated with the advanced fibrosis stage, had higher levels of drug sensitivity and immune checkpoint expression. In conclusion, the novel combined score could serve as a potential biomarker and contribute to improving the assessment of fibrosis stage in CHB patients. 相似文献
12.
目的 探讨FIB-4指数对慢性乙型肝炎肝纤维化的诊断价值.方法 212例慢性乙型肝炎患者行肝活检并同时留取血清标本,检测ALT、AST、PLT等指标,并根据其结果结合患者的年龄计算出FIB-4的数值.根据肝纤维化分期设定3个判定点,分别为显著纤维化(S2~S4期),严重纤维化(S3~S4期)和肝硬化(S4期).以肝活检病理结果为金标准绘制出FIB-4的受试者工作特征曲线(ROC),计算曲线下面积(AUC),评价其对慢性乙型肝炎肝纤维化的诊断价值.结果 212例肝活检患者中S0期3例(1.4%),S1期49例(23.1%),S2期66例(31.1%),S3期50例(23.6%),S4期44例(20.8%),即显著纤维化者(S2~S4期)160例(75.5%),严重纤维化者(S3~S4期)94例(44.3%),肝硬化者(S4期)44例(20.8%).FIB-4指数对3个判定点的AUC值分别为0.733(95%(CI:0.660~0.806,P〈0.01)、0.746(95%CI:0.679~0.813,P〈0.01)、0.756(95%CI:0.687~0.825,P〈0.01).结论 FIB-4指数是一种简单的、准确的、经济的非创性诊断方法,可以较准确地估计慢性乙型肝炎患者有无显著纤维化,使多数患者避免肝穿刺活检. 相似文献
13.
Lilian Yan Liang Hye Won Lee Vincent Wai-Sun Wong Terry Cheuk-Fung Yip Yee-Kit Tse Vicki Wing-Ki Hui Grace Chung-Yan Lui Henry Lik-Yuen Chan Grace Lai-Hung Wong 《Clinical and molecular hepatology》2021,27(3):499
Background/AimsSerum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients.MethodsFifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort.Results180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the time-dependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70–0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted.Conclusion: A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatment-naïve CHB patients with very low risk of HCC to be exempted from HCC surveillance. 相似文献
14.
目的 探讨乙型肝炎肝硬化患者乙型肝炎病毒(HBV)DNA水平与肝纤维化程度的关系及其临床意义.方法 回顾性分析2004年至2006年本科室收治的263例乙型肝炎肝硬化住院患者的临床资料.所有患者均进行肝功能Child-Pugh分级,检测HBV DNA、HBV血清标志物、透明质酸(HA)、人Ⅲ型前胶原(Hpc-Ⅲ)、Ⅳ型胶原(Ⅳ-C)、层粘蛋白(LN);行腹部超声检测脾大小、门静脉内径、脾静脉内径;胃镜检查食管静脉曲张程度,并记录常见并发症.根据HBV DNA水平分为4组:G1组,HBV DNA<103拷贝/ml;G2组,HBV DNA 103~<105拷贝/ml;G3组,HBV DNA 105~<107拷贝/ml;G4组,HBV DNA≥107拷贝/ml.比较各组间Child-Pugh分级、肝纤维化血清指标和门脉高压指标的差异以及各组肝硬化常见并发症的发生情况.结果 263例患者中217例(82.5%)HBV DNA阳性.不同HBV DNA水平患者之间的Child-Pugh评分分级、HA、Hpc-Ⅲ、Ⅳ-C、LN比较,差异无统计学意义(均P>0.05).4组患者之间脾大小、门静脉内径、脾静脉内径及食管静脉曲张程度比较,差异无统计学意义(均P>0.05).4组患者并发症如消化道出血、继发感染、腹水、肝性脑病、肝癌等发生率差异也无统计学意义(均P>0.05).结论 绝大部分乙型肝炎肝硬化患者HBV DNA阳性,但血清HBV DNA水平高低与肝硬化严重程度及并发症的发生率无明显关联. 相似文献
15.
Liver biopsy specimens from 58 American patients with chronic type B hepatitis were investigated for the presence and distribution of the hepatitis B core (HBcAg) and surface (HBsAg) antigens by peroxidase-anti-peroxidase techniques. HBsAg was detected in 43 (77%) and HBcAg in 52 (90%) patients. HBcAg was present in 50 of 51 (98%) patients with hepatitis B e antigen (HBeAg) but in only two of seven (29%) of patients with antibody to HBeAg (anti-HBe). There was no correlation between severity of hepatitis or height of aminotransferase activities and the amount of HBsAg or HBcAg in hepatocytes but there was a positive correlation between amount of HBcAg and height of HBV-DNA and DNA polymerase activity in serum. Follow-up liver biopsies, taken 1 to 3 yr later, were available from 39 patients. HBcAg remained detectable in 25 of 26 patients with persistence of HBeAg but disappeared in 12 patients who had lost HBeAg. In nine patients, HBcAg was cytoplasmic as well as nuclear in distribution. Seven of these patients had an intense lobular hepatitis with marked elevations in aminotransferase activities. These findings indicate that the amount of HBcAg in liver correlates with the amount of serum hepatitis B virus as quantified by serum levels of DNA polymerase and HBV-DNA. The amount of nuclear HBcAg does not correlate with the severity of the liver disease, but the presence of cytoplasmic HBcAg usually reflects an active and severe ongoing hepatitis. 相似文献
16.
Jung Hwan Yu Soon Gu Cho Young-Joo Jin Jin-Woo Lee 《Clinical and molecular hepatology》2022,28(3):351
Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral antiviral agents has significantly improved the prognosis of patients with CHB infection and reduced the risk of HCC. However, hepatitis B virus still remains a major factor in the development of HCC, raising many concerns. Therefore, numerous studies have been conducted to assess the risk of HCC in patients with CHB infection and many models have been proposed to predict the risk of developing HCC. However, as each study has different models for predicting HCC development that can be applied depending on the use of antiviral agents or the type of antiviral agents, it is necessary to properly understand characteristics of each model when using it for the evaluation of HCC in patients with CHB infection. In addition, because different variables such as host factor, viral activity, and cirrhosis are used to evaluate the risk of HCC development, it is necessary to assess the risk by carefully verifying which variables are used. Recently, studies have also evaluated the risk of HCC using risk prediction models through transient elastography and artificial intelligence (AI) system. These HCC risk predication models are also noteworthy. In this review, we aimed to compare HCC risk prediction models in patients with CHB infection reported to date to confirm variables used and specificity between each model to determine an appropriate HCC risk prediction method. 相似文献
17.
《Pathology, research and practice》2020,216(5):152876
PurposeThis research aimed to explore the correlation between miR-34a expression in peripheral blood and clinical characteristics of patients with chronic hepatitis C (CHC) as well as the diagnostic and prognostic values of serum miR-34a in CHC.MethodsSerum samples of 41 CHC patients and 18 normal participants were collected to examine the expression levels of miR-34a using qRT-PCR. The changes of serum TBA, liver enzyme AST and ALT were also determined by enzyme colorimetry and rate method. The levels of serum fibrotic markers hyaluronic acid (HA), type III procollagen (PCIII), type IV collagen (IV-C) and laminin (LN) were detected by radioimmunoassay. Degree of liver fibrosis was examined by liver biopsy. Western blot analysis was used to investigate the expression of ac-p53, p53 and Sirt1 in the liver tissues of CHC patients.ResultsMiR-34a was significantly increased in the serum of CHC patients than that in healthy participants, and serum miR-34a was correlated with liver fibrosis index. Serum TBA, AST and ALT levels, and AST/ALT ratios in patients with CHC were increased with increasing degree of fibrosis, and were positively associated with serum miR-34a. Furthermore, the liver tissues of CHC patients showed low Sirt1 protein expression and highly ac-p53 protein expression.ConclusionsSerum miR-34a in patients with CHC could promote liver fibrosis through mediating the Sirt1/p53 pathway and might function as pivotal biomarker on the prognosis and diagnosis of CHC patients. 相似文献
18.
目的 探究逍遥散治疗肝郁气滞症候乙型肝炎的近远期临床疗效,为临床研究提供参考依据.方法 选择2011年4月-2014年3月期间我院收治的82例乙型肝炎患者,按照随机数字法分为实验组和对照组,分别为40例与42例.对照组患者给予西利宾胺治疗实验组患者则服用逍遥散治疗.比较两组患者治疗前后肝功能指标的变化,分析两组患者治疗以后近远期临床疗效的差别.结果 治疗前,两组患者的ALT、AST以及TBIL的水平无差异性(P>0.05).治疗后,两组患者的ALT、AST以及TBIL的水平较治疗前均显著性降低,具有显著性差异(P<0.05),但实验组患者的三项生化指标的水平较对照组患者治疗后的水平降低更为明显,具有统计学意义(P<0.05);治疗后,实验组患者显效21例,有效16例,无效3例,总有效率92.5%,显著高于对照组患者的57.1%的总有效率,具有明显差异性(P<0.05);治疗前,两组患者的症候积分无显著差异(P>0.05).治疗0.5年、2年、3年后,两组患者的症候积分均降低,但实验组患者的症候积分与治疗前以及对照组患者治疗后,降低更为明显,均具有显著性差异(P<0.05).结论 使用逍遥散治疗肝郁气滞证侯乙型肝炎患者,能够显著降低ALT、AST以及TBIL的水平,提高乙型肝炎患者近期临床疗效,改善患者的远期中医证候积分,值得在临床上广泛推广. 相似文献
19.
复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床研究 总被引:3,自引:0,他引:3
目的验证复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床疗效和安全性。方法将420例慢性乙型肝炎肝纤维化患者随机分为两组:治疗组300例,口服复方鳖甲软肝片,对照组120例,口服和络舒肝胶囊,6个月为1疗程。结果治疗组的患者在改善症状和体征,恢复肝功能总疗效方面,显效率和总有效率分别为55.67%和81.67%,对照组分别为15.80%和60.00%,治疗组明显优于对照组(P〈0.01)。结论复方鳖甲软肝片在改善中医症状,血清学肝纤维化及肝组织病理指标等方面疗效确切,可以有效治疗慢性乙型肝炎肝纤维化。 相似文献
20.
目的 探讨HBeAg阴性慢性乙型肝炎和HBeAg阳性慢性乙型肝炎患者的临床特征.方法 回顾性分析96例慢性乙型肝炎患者的临床资料,包括肝功能、HBV DNA定量及肝组织病理学检查等.结果 96例慢性乙型肝炎患者中,38例为HBeAg阴性慢性乙型肝炎患者,平均年龄为32±8岁;58例为HBeAg阳性患者,平均年龄为35±8岁,两组比较无统计学差异(t=1.546,P=0.125).两组患者在丙氨酸转氨酶(ALT)水平比较无统计学差异(x2=0.056,P =0.81).HBeAg阴性组HBVDNA水平为4.28±0.97 copies/mL,HBeAg阳性组HBV DNA水平为6.12±1.16 copies/mL,两组比较有统计学差异(t=10.32,P <0.001).45例患者进行了肝组织病理穿刺检查术,HBeAg阴性组11例,HBeAg阳性组34例.两组患者在炎症程度差别无统计学意义(x2=3.053,P=0.238),在纤维化程度差别有统计学意义(x2 =6.000,P=0.048).结论 HBeAg阴性患者的平均年龄与HBeAg阳性者没有统计学差异,HBV DNA载量低于HBeAg阳性组,肝脏组织纤维化程度较HBeAg阳性组严重.HBeAg阴性组ALT水平和肝脏组织炎症程度与HBeAg阳性组无差异. 相似文献